International Journal of Innovative Computer Science and IT Research

Volume 2, Issue 9 – September 2026 • E-ISSN: 3067-1108 P-ISSN: 3067-1094

Technology Convergence in Healthcare: Connecting Neuroscience, Genomics, Robotics and Artificial Intelligence

Jocelyne Bloch

Professor, University of Lausanne (UNIL), Switzerland

Abstract

Healthcare innovation increasingly develops through the convergence of previously separate scientific and technological fields. Neuroscience provides information about neural structure, function, plasticity, cognition, and disease. Genomics identifies inherited and acquired molecular variations that may influence biological pathways, disease susceptibility, and treatment response. Robotics extends clinical capabilities through precise movement, physical assistance, rehabilitation, and remote intervention. Artificial intelligence offers computational methods for recognizing complex patterns, integrating heterogeneous data, supporting predictions, and adapting technological responses. When connected within a clinically governed system, these domains may support more individualized diagnosis, treatment planning, rehabilitation, and longitudinal care.

This paper examines an interdisciplinary framework for converging neuroscience, genomics, robotics, and artificial intelligence in healthcare. A conceptual review is combined with an illustrative simulation assessing how progressively integrated technological layers may affect a normalized personalized-care capability index. The simulated index increases from 52 for isolated clinical and biological data to 93 when multimodal artificial intelligence and closed-loop robotic intervention are incorporated. These values are hypothetical analytical illustrations and do not represent clinical-trial findings, treatment efficacy, diagnostic accuracy, or patient outcomes.

The analysis identifies potential applications in neurological diagnosis, neurorehabilitation, precision oncology, rare-disease evaluation, assistive robotics, brain–computer interfaces, robotic surgery, and adaptive therapeutics. It also reveals substantial challenges involving data incompatibility, limited sample diversity, biological uncertainty, algorithmic bias, robotic safety, cybersecurity, informed consent, incidental genomic findings, neural privacy, and unequal access.

Technology convergence should therefore be implemented through clinically defined purposes, modular validation, prospective evaluation, human oversight, secure data governance, and clearly assigned accountability. The paper concludes that convergence has value when it strengthens clinical reasoning and patient capability rather than pursuing technological integration as an end in itself.

Keywords: technology convergence; neuroscience; genomics; healthcare robotics; artificial intelligence; precision medicine; neurotechnology; personalized healthcare.

International Journal of Innovative Computer Science and IT Research

Volume 2, Issue 9 – September 2026 ● E-ISSN: 3067-1108 P-ISSN: 3067-1094

1. Introduction

Healthcare systems generate increasingly diverse forms of information. Clinical records describe symptoms, diagnoses, treatments, and outcomes. Medical imaging reveals anatomical and functional characteristics. Genomic sequencing identifies molecular variation. Wearable and implantable devices capture physiological activity, while robotic systems interact physically with patients and clinicians. These sources are frequently developed and managed through separate technical infrastructures, disciplinary traditions, and regulatory processes. Their isolation limits the ability to construct an integrated understanding of complex disease.

Technology convergence refers to the purposeful connection of different scientific and engineering capabilities within a shared clinical objective. In healthcare, convergence does not simply mean placing several devices or datasets in the same institution. It requires meaningful relationships among biological measurement, computational interpretation, clinical judgment, physical intervention, and outcome monitoring. A convergent system may use neural signals to characterize functional impairment, genomic information to clarify biological mechanisms, artificial intelligence to integrate these findings, and robotics to deliver or adjust an intervention.

Neuroscience contributes information across multiple scales. Structural and functional imaging can reveal patterns associated with injury or neurological disease. Electroencephalography and related signals can represent aspects of neural activity. Behavioral and cognitive assessments describe functional consequences that cannot be inferred solely from images. Neuroscience also provides knowledge of neural plasticity, which is particularly relevant to rehabilitation because repeated, task-specific practice can influence functional recovery.

Genomics adds a molecular and inherited dimension. Genetic variants may contribute to disease susceptibility, drug metabolism, treatment response, or rare disorders. Tumor sequencing can identify molecular characteristics that may inform targeted treatment. However, genomic associations are often probabilistic, context-dependent, and unequally studied across populations. A detected variant does not automatically explain a patient’s condition or establish the appropriate treatment.

Robotics connects digital intelligence with physical action. Surgical robots can support controlled instrument movement, while rehabilitation robots can provide repetitive assistance and measure movement performance. Prosthetic and assistive devices may interpret muscular, neural, or mechanical signals to support mobility and daily activity. Once a computational model controls a physical system, errors can directly affect a patient, making safety constraints and human override essential.

Artificial intelligence can help integrate high-dimensional and multimodal information. Machine-learning systems may recognize patterns across imaging, genomic, physiological, behavioral, and clinical data that are difficult to examine manually. Yet predictive accuracy does not establish clinical usefulness. Convergent healthcare systems require prospective evaluation, interpretable outputs, appropriate comparison standards, workflow integration, and evidence that their use improves a clinically meaningful outcome.

2. Review of Literature

2.1 Neuroscience, Genomics, and Biological Individuality

Neuroscience has increasingly moved toward multimodal analysis. Structural imaging, functional imaging, electrophysiology, behavioral testing, and clinical history provide complementary perspectives on neurological conditions. Each modality has limitations. Imaging may reveal anatomical differences without explaining their functional significance, while neural recordings can provide temporal detail but may be sensitive to noise, movement, and electrode placement.

Machine learning has been used to classify neurological patterns and estimate progression or treatment response. Arbabshirani and colleagues examined the movement of neuroimaging-based machine learning toward clinical practice and emphasized the importance of external validation, representative samples, and evaluation under realistic conditions. Models developed from narrowly selected research cohorts may perform differently when applied to clinically diverse populations.

Genomic medicine provides another layer of biological characterization. Ashley described the emerging clinical implications of interpreting complete human genomes, including their possible contribution to diagnosis and individualized medical decision-making. Subsequent developments in sequencing and bioinformatics have expanded opportunities for evaluating rare diseases, cancer, pharmacogenomics, and inherited risk.

The interpretation of genomic information remains difficult. Many variants have uncertain significance, while the effect of a particular variant may depend on ancestry, environment, gene regulation, age, and other biological factors. Genomic predictions derived mainly from one population may not transfer reliably to another. Clinical use therefore requires validated interpretation, genetic counseling, and caution against deterministic conclusions.

Connecting neuroscience with genomics may improve understanding of neurological heterogeneity. Individuals with similar symptoms may have different molecular mechanisms, while the same genetic alteration may produce different clinical manifestations. Integrated analysis can generate more refined biological subgroups, but such subgroups require independent confirmation before they guide treatment.

2.2 Robotics and Adaptive Clinical Intervention

Healthcare robotics includes surgical systems, rehabilitation devices, prostheses, exoskeletons, hospital-service robots, and socially assistive platforms. In surgical settings, robotic systems can improve instrument articulation, stabilize movement, and support minimally invasive access. Clinical outcomes depend on the procedure, surgical team, training, patient selection, and comparison with established techniques rather than on the presence of robotics alone.

Rehabilitation robots can deliver repeated and measurable movement practice. Lo and colleagues evaluated robot-assisted therapy for long-term upper-limb impairment after stroke and demonstrated the need to compare robotic intervention with intensive conventional care rather than minimal treatment. Robotics may support treatment intensity and measurement, but therapeutic value depends on appropriate task design and integration with professional rehabilitation.

Assistive robotics can respond to residual muscular, neural, or movement signals. Intelligent prostheses may estimate user intent and adjust control parameters, while exoskeletons can support gait or upper-limb movement. These systems create a shared adaptation process: the device learns from the user, and the user learns how to control the device.

Brain–computer interfaces provide a direct connection between neural activity and external equipment. They may enable communication or device control for individuals with severe motor impairment. Millán and colleagues described the importance of designing brain–machine interfaces around user capability, training, signal variability, feedback, and practical usability. Laboratory performance alone does not establish everyday clinical benefit.

Robotic systems increasingly incorporate artificial intelligence for perception, navigation, intention estimation, and adaptive assistance. This combination can improve responsiveness but also complicates validation. A continuously adapting controller may not behave identically to the initially tested model. Safety-critical limits should therefore remain protected from autonomous modification.

2.3 Artificial Intelligence as an Integrative Layer

Artificial intelligence is relevant to technology convergence because it can model relationships across multiple data types. Topol characterized high-performance medicine as a partnership between human expertise and computational intelligence. Such partnership is most defensible when AI expands analytical capacity while clinicians retain responsibility for contextual interpretation and patient care.

Rajkomar and colleagues reviewed machine learning in medicine and highlighted applications involving diagnosis, prognosis, treatment selection, workflow support, and data representation. They also identified limitations involving bias, generalizability, interpretability, and integration into clinical practice. A technically accurate model may fail if it does not address a meaningful clinical decision.

Multimodal systems can combine clinical records, images, molecular measurements, physiological signals, and patient-reported information. The main challenge is not merely combining a large number of variables. The system must account for missing data, different measurement frequencies, inconsistent coding, unequal data quality, and relationships that may change over time.

Artificial intelligence can also connect assessment with intervention. A model may estimate a patient’s movement intention and direct a rehabilitation robot, or integrate genomic and clinical information to prioritize possible therapeutic options. In these cases, the algorithm becomes part of a decision-and-action pathway. Validation must therefore examine the complete pathway rather than model accuracy in isolation.

The World Health Organization’s guidance on AI for health emphasizes autonomy, well-being, transparency, accountability, inclusiveness, and sustainability. These principles are directly relevant to convergent systems because the combination of neural, genomic, clinical, and behavioral information can create unusually sensitive personal profiles. Ethical governance should be incorporated during system design rather than added after deployment.

3. Objectives of the Study

3.1 Scientific Integration Objectives

The first objective is to examine how neuroscience, genomics, robotics, and artificial intelligence contribute distinct but complementary capabilities to healthcare. The study seeks to identify the clinical relationships among neural function, molecular variation, computational inference, and physical intervention.

A related objective is to distinguish meaningful convergence from superficial technological combination. Technologies are considered convergent only when their integration supports a defined clinical question, reduces uncertainty, improves an intervention, or produces a measurable patient-centered benefit.

3.2 Clinical and Technological Objectives

The second objective is to develop a conceptual architecture for multimodal data integration and closed-loop clinical intervention. The framework connects biological measurement, AI-assisted interpretation, clinical review, robotic or digital action, and outcome-based feedback.

The study also evaluates possible applications in neurological care, rehabilitation, assistive technologies, precision oncology, rare-disease assessment, robotic surgery, and personalized treatment planning. It does not claim that these applications have equivalent maturity or evidence.

3.3 Safety and Governance Objectives

The third objective is to identify technical, ethical, regulatory, and institutional safeguards for convergent healthcare systems. These safeguards include modular validation, cybersecurity, data minimization, informed consent, uncertainty reporting, algorithmic audit, human override, and post-deployment monitoring.

The paper further examines whether convergence could intensify inequity when genomic sequencing, advanced imaging, robotics, or computational infrastructure are accessible only to well-resourced institutions and populations.

4. Research Methodology

4.1 Research Design and Evidence Strategy

The study adopted a conceptual and simulation-based research design. Literature was examined across neuroscience, genomic medicine, biomedical artificial intelligence, neurotechnology, robotic surgery, rehabilitation robotics, and health-technology governance. No patients, clinical interventions, biological samples, or identifiable records were included.

The analytical search covered peer-reviewed journal articles, major clinical studies, biomedical engineering research, and authoritative institutional guidance. Search concepts included "AI neuroscience clinical translation," "genomic precision medicine," "rehabilitation robotics," "brain–computer interface healthcare," "robotic surgery artificial intelligence," and "multimodal healthcare data integration."

Eligible sources addressed at least one of the four convergence domains and contained clinically relevant discussion of diagnosis, intervention, validation, implementation, or governance. Purely promotional materials, unsupported technical claims, and sources without clear healthcare relevance were excluded from the core conceptual synthesis.

Evidence was organized according to technological function, clinical application, validation requirement, and principal risk. Foundational literature was used to define the domains, while clinically oriented studies supported analysis of implementation and patient-level implications.

4.2 Convergent Healthcare Architecture

The framework contains five connected stages: multimodal biological measurement, standardized data representation, AI-assisted integration, clinician-supervised intervention, and longitudinal outcome feedback. The architecture does not assume that every patient or clinical problem requires every data modality.

Table 1: Functional Architecture of Healthcare Technology Convergence

Convergence layer	Representative information or capability	Intended clinical contribution	Required safeguard
Neuroscience	Imaging, neural signals, cognition and behavior	Characterizes neural structure and function	Clinically contextual interpretation
Genomics	Germline, somatic and pharmacogenomic information	Identifies molecular variation and possible mechanisms	Validated interpretation and counseling
Artificial intelligence	Multimodal fusion, classification and prediction	Integrates complex evidence and estimates uncertainty	External validation and human review
Healthcare robotics	Surgical, rehabilitative and assistive action	Translates decisions into precise physical support	Independent safety boundaries
Outcome feedback	Functional, clinical and patient-reported response	Supports monitoring and bounded adaptation	Continuous oversight and withdrawal options

Each layer must retain traceability. A clinician should be able to identify which observations contributed to an output, whether the information was measured or inferred, and how uncertainty was represented. A system that produces a recommendation without preserving this distinction may create false confidence.

4.3 Illustrative Simulation Procedure

The values were selected to demonstrate a conceptual progression rather than estimate a clinically observed effect. They are not diagnostic sensitivity, treatment-response rates, surgical outcomes, rehabilitation gains, survival estimates, or validated composite scores.

The simulation assumes accurate measurement, interoperable systems, appropriate consent, representative training data, and effective clinical review. Real healthcare environments may not satisfy these assumptions, and additional technological components can introduce errors as well as benefits.

5. Analysis

5.1 Integrating Biological and Clinical Evidence

Neuroscience and genomics describe different aspects of biological individuality. Neural imaging and electrophysiological signals can characterize present structure or function, while genomic information may indicate inherited susceptibility, molecular mechanisms, or treatment-related variation. Neither source independently provides a complete representation of a patient's condition.

A convergent system may be particularly useful when clinical presentation is heterogeneous. Patients with similar neurological symptoms may differ in affected pathways, genetic background, progression, and rehabilitation potential. Multimodal analysis can help identify subgroups or generate hypotheses, but clinical validation remains necessary because computational similarity does not prove a common biological cause.

Temporal alignment is a major analytical problem. A genome remains broadly stable, whereas neural activity, medication exposure, symptoms, and functional ability can change over minutes, days, or years. Models must distinguish relatively stable characteristics from dynamic states and treatment-induced changes.

Missing data should be represented explicitly. Not every patient will undergo genomic sequencing, advanced imaging, or continuous physiological monitoring. A model trained on complete research datasets may behave unpredictably when applied to routine clinical records containing missing or irregular measurements.

5.2 Simulated Convergence Results

Table 2: Illustrative Personalized-Care Capability Across Convergence Stages

Technology configuration	Capability index	Incremental gain	Cumulative gain
Isolated clinical and biological assessment	52	—	—
Integration of neuroscience data	64	12	12
Addition of genomic characterization	75	11	23
AI-assisted multimodal integration	86	11	34
Closed-loop robotic intervention and feedback	93	7	41

International Journal of Innovative Computer Science and IT Research
Volume 2, Issue 9 – September 2026 ● E-ISSN: 3067-1108 P-ISSN: 3067-1094

The initial increase reflects the assumed value of adding direct information about neural structure, activity, cognition, or behavior. Genomic characterization contributes a molecular layer that may clarify mechanisms or treatment-related variation in selected conditions.

AI-assisted integration generates a further increase because it connects the available data rather than treating each modality separately. The simulation assumes that the model has been trained on representative information and independently validated. Without these conditions, multimodal complexity could increase error instead of reducing it.

The smaller final gain represents the specialized contribution of robotics and outcome feedback. Robotics does not improve every healthcare pathway. Its benefit arises primarily when a precise physical action, repeated training, assistive function, or adaptive intervention is clinically appropriate.

Graph 1: Illustrative Growth in Personalized-Care Capability Through Technology Convergence



Supporting data: Isolated assessment = 52; neuroscience integration = 64; genomic characterization = 75; AI-assisted multimodal integration = 86; closed-loop robotic intervention and feedback = 93.
Source: Author-developed illustrative simulation; values do not represent clinical performance or patient outcomes.
Interpretation: The simulated capability index increases as complementary biological, computational, and intervention layers are integrated. The progression illustrates the potential value of connecting information across scales, from molecular variation to neural function and physical intervention.
Key Finding: Technology convergence may increase the informational and adaptive capacity of healthcare, but additional complexity creates value only when each component is clinically justified, independently validated, interoperable, and governed within a safe care pathway.

5.3 Clinical Application Pathways

In neurological diagnosis, AI may integrate imaging, neural signals, cognitive assessments, movement data, and genomic findings. Such integration could support disease classification or progression assessment, although outputs must remain linked to clinically accepted diagnostic processes. A model should not convert uncertain molecular or imaging patterns into definitive diagnoses.

In neurorehabilitation, robotic devices can provide task-specific movement assistance while sensors measure effort, trajectory, muscle activation, or neural response. AI may adjust assistance within therapist-defined boundaries. Outcome feedback can indicate whether the intervention supports functional improvement or merely improves performance on the device.

Assistive technologies may translate muscular or neural signals into wheelchair, prosthetic, communication, or environmental-control commands. Personalization can improve usability because signal patterns differ among users. Systems must also offer reliable manual or alternative controls when automated interpretation fails.

Precision oncology offers another convergence pathway. Tumor genomics, pathology, imaging, clinical history, and treatment outcomes may be analyzed together to support molecular characterization and therapeutic evaluation. AI-generated recommendations should be reviewed through multidisciplinary clinical processes and should distinguish approved treatments, clinical-trial options, and research hypotheses.

Robotic surgery may incorporate imaging, navigation, instrument tracking, and AI-assisted recognition. The surgeon remains responsible for interpreting anatomy, managing unexpected conditions, and deciding whether to continue, modify, or stop a procedure. Increasing automation requires evidence appropriate to the level of autonomy.

6. Challenges

6.1 Data Integration and Scientific Uncertainty

Neural, genomic, robotic, imaging, and clinical systems often use different formats, identifiers, measurement standards, and quality-control procedures. Data may also be generated at incompatible timescales. Technical interoperability is necessary, but semantic interoperability is equally important because the same clinical concept may be defined differently across institutions.

High-dimensional datasets can create misleading associations when sample sizes are small. Genomic variables, imaging features, and physiological signals may greatly exceed the number of available patients. Without strong validation, models can learn institution-specific artifacts rather than biologically meaningful relationships.

Biological relationships are not necessarily causal. An AI system may identify an association between a genomic feature, neural pattern, and clinical outcome without demonstrating why the relationship exists. Treatment decisions require stronger evidence than exploratory prediction.

6.2 Robotic Safety and Adaptive-System Reliability

Robotic systems physically interact with patients and clinical environments. Errors may arise from sensors, mechanical components, calibration, control software, communication delays, or incorrect AI inference. Multiple safety layers are needed so that failure of one component does not cause uncontrolled movement.

Adaptive systems create an additional challenge because their behavior may change after initial validation. Learning should occur within predefined limits. Maximum force, permitted movement range, emergency stopping, collision prevention, and prohibited actions should remain outside autonomous modification.

Simulation and laboratory testing are insufficient for complete clinical evaluation. Devices should be tested under realistic conditions involving variable anatomy, fatigue, unexpected movement, workflow interruptions, and different levels of professional experience.

6.3 Privacy, Consent, Equity, and Accountability

Genomic information can reveal inherited characteristics relevant not only to the patient but also to biological relatives. Neural data may contain information about health, behavior, attention, or cognitive state. When combined with clinical and behavioral records, these data can create a highly detailed personal profile.

Consent should specify which information is collected, how it is integrated, whether it will be reused for model development, and how incidental findings will be managed. Patients should understand which outputs are established clinical findings and which are algorithmic predictions.

Technological convergence may widen inequality. Institutions with advanced sequencing, imaging, robotics, and computing infrastructure may deliver services unavailable elsewhere. Training datasets may underrepresent populations with limited access, causing poorer performance precisely where health-system resources are already constrained.

Responsibility must remain traceable. Clinicians, hospitals, software developers, robotic-device manufacturers, sequencing laboratories, and data providers may all influence the final output. Governance should define who investigates failures, communicates risk, corrects models, and supports patients affected by error.

7. Discussion

7.1 Convergence as a Clinically Directed Process

The analysis indicates that convergence should begin with a clinical need rather than with the availability of technology. A patient should not undergo genomic sequencing, neural monitoring, or robotic intervention merely because these technologies can be connected. Each component should address a defined uncertainty or therapeutic requirement.

A modular approach supports more defensible implementation. Neuroscience data may be sufficient for one clinical task, while another may require molecular information. Robotics is appropriate only when physical interaction or repeated assistance contributes to the intended outcome. Artificial intelligence should integrate relevant evidence rather than indiscriminately maximize data volume.

The simulated increase in personalized-care capability represents an idealized analytical possibility. It does not show that a four-domain system will outperform a simpler clinical pathway. Comparative evaluation should determine whether convergence produces sufficient benefit to justify additional cost, complexity, burden, and risk.

7.2 Human Expertise and Closed-Loop Care

Healthcare professionals contribute causal reasoning, contextual understanding, interpersonal communication, and ethical judgment. Genetic counselors interpret hereditary implications, neuroscientists evaluate neural evidence, therapists understand functional performance, surgeons manage physical intervention, and patients contribute their goals and lived experience.

Artificial intelligence can connect and prioritize information, while robotics can deliver measurable physical action. Neither replaces the need for human interpretation. The most credible model is one in which computational and robotic capabilities operate within an accountable multidisciplinary team.

Closed-loop care also requires patient feedback. A technically successful intervention may cause discomfort, fatigue, anxiety, or disruption to daily life. Patient-reported outcomes and personal priorities should influence whether adaptation continues. Optimization should not be limited to variables that a device can measure automatically.

7.3 Responsible Translation and Health-System Readiness

Translation requires evaluation of the complete sociotechnical system. Strong model accuracy does not compensate for poor workflow integration, unsafe robotics, weak consent, incompatible data, or absence of professional training. Clinical impact depends on how the technology interacts with existing services and responsibilities.

Prospective studies should compare convergent systems with appropriate standards of care. Outcomes may include diagnostic time, functional improvement, adverse events, patient experience, clinician workload, accessibility, and cost. Reporting should distinguish exploratory prototypes, retrospective models, controlled evaluations, and routine clinical use.

The places human autonomy, safety, transparency, accountability, inclusiveness, and sustainability at the center of health-AI governance. These principles are especially important for convergent platforms because errors or misuse can extend across biological interpretation, clinical decisions, and physical intervention.

8. Conclusion

Technology convergence can connect neuroscience, genomics, robotics, and artificial intelligence across a continuous healthcare pathway. Neuroscience describes neural structure and function, genomics contributes molecular context, artificial intelligence integrates heterogeneous evidence, and robotics translates selected decisions into physical assistance or intervention. Outcome feedback can then support monitoring and carefully bounded adaptation.

The illustrative simulation shows a conceptual increase in personalized-care capability as additional technological layers are incorporated. These values are not empirical evidence and should not be interpreted as improved diagnostic accuracy, treatment efficacy, rehabilitation outcome, or patient survival. Real benefit requires prospective comparison with established care using clinically meaningful outcomes.

The principal challenge is not simply developing more powerful algorithms or more advanced devices. Convergent systems must manage biological uncertainty, incompatible data, limited sample diversity, changing patient conditions, robotic risk, cybersecurity, privacy, incidental findings, and unequal access. Every inferred result should remain distinguishable from directly measured evidence.

Responsible convergence should remain clinically directed, modular, explainable, and accountable. Patients should retain meaningful consent, privacy, and withdrawal options, while professionals should retain authority over diagnosis and intervention. Safety-critical robotic functions require independent limits and reliable manual override.

The long-term value of healthcare convergence will depend on whether it improves patient capability, clinical understanding, and equitable access rather than merely increasing technological complexity. Its most defensible form is a human-centered partnership in which biological science, computational intelligence, professional expertise, and patient priorities remain connected throughout the care process.

References

1. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine, 25*, 44–56. https://doi.org/10.1038/s41591-018-0300-7
2. Rajkomar, A., Dean, J., & Kohane, I. (2019). Machine learning in medicine. *New England Journal of Medicine, 380*(14), 1347–1358. https://doi.org/10.1056/NEJMra1814259
3. Esteva, A., Robicquet, A., Ramsundar, B., Kuleshov, V., DePristo, M., Chou, K., Cui, C., Corrado, G., Thrun, S., & Dean, J. (2019). A guide to deep learning in healthcare. *Nature Medicine, 25*, 24–29. https://doi.org/10.1038/s41591-018-0316-z
4. Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in health care. *JAMA, 319*(13), 1317–1318. https://doi.org/10.1001/jama.2017.18391
5. LeCun, Y., Bengio, Y., & Hinton, G. (2015). Deep learning. *Nature, 521*, 436–444. https://doi.org/10.1038/nature14539
6. Libbrecht, M. W., & Noble, W. S. (2015). Machine learning applications in genetics and genomics. *Nature Reviews Genetics, 16*, 321–332. https://doi.org/10.1038/nrg3920
7. Eraslan, G., Avsec, Ž., Gagneur, J., & Theis, F. J. (2019). Deep learning: New computational modelling techniques for genomics. *Nature Reviews Genetics, 20*, 389–403. https://doi.org/10.1038/s41576-019-0122-6
8. Zou, J., Huss, M., Abid, A., Mohammadi, P., Torkamani, A., & Telenti, A. (2019). A primer on deep learning in genomics. *Nature Genetics, 51*, 12–18. https://doi.org/10.1038/s41588-018-0295-5
9. Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., Bridgland, A., Meyer, C., Kohl, S. A. A., Ballard, A. J., Cowie, A., Romera-Paredes, B., Nikolov, S., Jain, R., Adler, J., … Hassabis, D. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature, 596*, 583–589. https://doi.org/10.1038/s41586-021-03819-2
10. Miotto, R., Wang, F., Wang, S., Jiang, X., & Dudley, J. T. (2018). Deep learning for healthcare: Review, opportunities and challenges. *Briefings in Bioinformatics, 19*(6), 1236–1246. https://doi.org/10.1093/bib/bbx044

11. Litjens, G., Kooi, T., Bejnordi, B. E., Setio, A. A. A., Ciompi, F., Ghafoorian, M., van der Laak, J. A. W. M., van Ginneken, B., & Sánchez, C. I. (2017). A survey on deep learning in medical image analysis. *Medical Image Analysis, 42*, 60–88. https://doi.org/10.1016/j.media.2017.07.005
12. Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. *Nature, 542*, 115–118. https://doi.org/10.1038/nature21056
13. Topol, E. J. (2012). The creative destruction of medicine: How the digital revolution will create better health care. *Basic Books*.
14. Shen, D., Wu, G., & Suk, H.-I. (2017). Deep learning in medical image analysis. *Annual Review of Biomedical Engineering, 19*, 221–248. https://doi.org/10.1146/annurev-bioeng-071516-044442
15. Yang, G.-Z., Nelson, B. J., Murphy, R. R., Chaytor, A., Hu, Y., Hughes, C., Nguyen, H., Shen, Y., & Sitti, M. (2018). Medical robotics—Regulatory, ethical, and legal considerations for increasing levels of autonomy. *Science Robotics, 3*(23), eaar6820. https://doi.org/10.1126/scirobotics.aar6820
16. Hashimoto, D. A., Rosman, G., Rus, D., & Meireles, O. (2018). Artificial intelligence in surgery: Promises and perils. *Annals of Surgery, 268*(1), 70–76. https://doi.org/10.1097/SLA.0000000000002693
17. Yang, G.-Z., Bellingham, J., Dupont, P. E., Fischer, P., Floridi, L., Full, R., Jacobstein, N., Kumar, V., McNutt, M., Merrifield, R., Nelson, B. J., Sitti, M., Taylor, R., & Wood, R. (2018). The grand challenges of Science Robotics. *Science Robotics, 3*(14), eaar7650. https://doi.org/10.1126/scirobotics.aar7650
18. Silvera-Tawil, D. (2024). Robotics in healthcare: A survey. *SN Computer Science, 5*, Article 189. https://doi.org/10.1007/s42979-023-02551-0
19. Deo, N., & Anjankar, A. (2023). Artificial intelligence with robotics in healthcare: A narrative review of its viability in India. *Cureus, 15*(5), e39416. https://doi.org/10.7759/cureus.39416
20. Zawacki-Richter, O., Marín, V. I., Bond, M., & Gouverneur, F. (2019). Systematic review of research on artificial intelligence applications in higher education—Where are the educators? *International Journal of Educational Technology in Higher Education, 16*, Article 39. https://doi.org/10.1186/s41239-019-0171-0